Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a widespread chronic microvascular complication of diabetes mellitus (DM), affects almost 30–50% of patients, and represents a leading cause of death of DM. Serotonin or 5-hydroxytryptamine (5-HT) is a multifunctional bioamine that has crucial roles in many physiolog...
Saved in:
Main Authors: | Yu Yang, Hui Huang, Zheng Xu, Jun-kai Duan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2017/7680576 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serotonin Receptors in Hippocampus
by: Laura Cristina Berumen, et al.
Published: (2012-01-01) -
New Insights into Diabetic Kidney Disease: The Potential Pathogenesis and Therapeutic Targets
by: Wei Jing Liu, et al.
Published: (2017-01-01) -
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
by: Stephanie Toth-Manikowski, et al.
Published: (2015-01-01) -
Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets
by: Akira Mima
Published: (2013-01-01) -
A Case of the Serotonin Syndrome Secondary to Phenelzine Monotherapy at Therapeutic Dosing
by: A. Malik, et al.
Published: (2015-01-01)